iX Biopharma Ltd. (SGX:42C)

Market Cap	17.67M
Revenue (ttm)	7.00M
Net Income (ttm)	-9.72M
Shares Out	n/a
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	130,765
Open	0.0210
Previous Close	0.0210
Day's Range	0.0210 - 0.0210
52-Week Range	0.0170 - 0.0570
Beta	n/a
RSI	40.28
Earnings Date	May 9, 2025

About iX Biopharma

iX Biopharma Ltd., a specialty pharmaceutical and nutraceutical company, develops, manufactures, and commercializes therapies for the treatment of acute and breakthrough pain, and other health conditions in Singapore, the United States, China, and Australia. The company operates through Specialty Pharmaceutical and Nutraceutical segments. It offers Wafesil and Silcap for the treatment of male erectile dysfunction; and Xativa, a sublingual cannabidiol wafer, as well as Hypera, a sublingual tetrahydrocannabinol wafer for chronic pain, anxiety, an...

• Industry: Pharmaceutical Preparations
• Founded: 2004
• Employees: 42
• Stock Exchange: Singapore Exchange
• Ticker Symbol: 42C

Financial Performance

In 2024, iX Biopharma's revenue was 5.96 million, an increase of 0.78% compared to the previous year's 5.91 million. Losses were -10.79 million, 12.3% more than in 2023.